Mamoun B Al-nouri, MD | |
2700 W 9th Ave, Ste 106, Oshkosh, WI 54904-7247 | |
(920) 236-1755 | |
Not Available |
Full Name | Mamoun B Al-nouri |
---|---|
Gender | Male |
Speciality | Internal Medicine - Cardiovascular Disease |
Location | 2700 W 9th Ave, Oshkosh, Wisconsin |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1104810100 | NPI | - | NPPES |
30233300 | Medicaid | WI |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RC0000X | Internal Medicine - Cardiovascular Disease | 21963 (Wisconsin) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mamoun B Al-nouri, MD 2700 W 9th Ave, Ste 106, Oshkosh, WI 54904-7247 Ph: (920) 236-1755 | Mamoun B Al-nouri, MD 2700 W 9th Ave, Ste 106, Oshkosh, WI 54904-7247 Ph: (920) 236-1755 |
News Archive
In this interview, Tim Cross, Director of the NMR and MRI programs at the National High Magnetic Field Lab (NHMFL) in Tallahassee, Florida, talks about his research into protein structures in viruses and bacteria, and how the findings will affect medical research into disease prevention.
Shire plc, the global specialty biopharmaceutical company, announces that the United States District Court for the District of Columbia ("Court"), following extensive briefing by the parties and an oral hearing, has upheld the decision of the U.S. Food and Drug Administration ("FDA") to grant 5-year New Chemical Entity ("NCE") exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).
Uniqsis reports how chemists at the School of Pharmacy, University College London (UK) have been using a FlowSyn continuous flow reactor system.
Array BioPharma today reported top-line results from the ongoing Phase 3 clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma, known as the NEMO trial. The study met its primary endpoint of improving progression-free survival (PFS) compared with dacarbazine treatment.
› Verified 4 days ago
Zahid N Dar, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 855 N Westhaven Dr, Oshkosh, WI 54904 Phone: 920-303-8700 | |
Dr. Brian A.w. Temple, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 855 N Westhaven Dr, Oshkosh, WI 54904 Phone: 920-303-8700 Fax: 920-303-8992 | |
Anita I Gheller-rigoni, DO Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 855 N Westhaven Dr, Oshkosh, WI 54904 Phone: 920-456-5900 Fax: 920-456-5901 | |
Maye R Berroya, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 855 N Westhaven Dr, Oshkosh, WI 54904 Phone: 920-456-7408 | |
Dr. Benjamin Joseph Heinzen, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1855 S Koeller St, Oshkosh, WI 54902 Phone: 920-223-7100 | |
Robert D. Geck, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 855 N Westhaven Dr, Oshkosh, WI 54904 Phone: 920-303-8700 |